Novel Mitochondria-targeted Drugs for Cancer Therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10428045" target="_blank" >RIV/00216208:11110/21:10428045 - isvavai.cz</a>
Alternative codes found
RIV/00159816:_____/21:00075814 RIV/00216224:14110/21:00118840 RIV/00064165:_____/21:10428045 RIV/62156489:43210/21:43919636 RIV/60461373:22340/21:43920745
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=DvlGH_9C3-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=DvlGH_9C3-</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1389557520666201118153242" target="_blank" >10.2174/1389557520666201118153242</a>
Alternative languages
Result language
angličtina
Original language name
Novel Mitochondria-targeted Drugs for Cancer Therapy
Original language description
The search for mitochondria-targeted drugs has dramatically risen over the last decade. Mitochondria are essential organelles serving not only as a powerhouse of the cell but also as a key player in cell proliferation and cell death. Their central role in the energetic metabolism, calcium homeostasis and apoptosis makes them an intriguing field of interest for cancer pharmacology. In cancer cells, many mitochondrial signaling and metabolic pathways are altered. These changes contribute to cancer development and progression. Due to changes in mitochondrial metabolism and changes in membrane potential, cancer cells are more susceptible to mitochondria-targeted therapy. The loss of functional mitochondria leads to the arrest of cancer progression and/or a cancer cell death. Identification of mitochondrial changes specific for tumor growth and progression, rational development of new mitochondria-targeted drugs and research on delivery agents led to the advance of this promising area. This review will highlight the current findings in mitochondrial biology, which are important for cancer initiation, progression and resistance, and discuss approaches of cancer pharmacology with a special focus on the anti-cancer drugs referred to as 'mitocans'.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Mini-Reviews in Medicinal Chemistry
ISSN
1389-5575
e-ISSN
—
Volume of the periodical
21
Issue of the periodical within the volume
7
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
17
Pages from-to
816-832
UT code for WoS article
000631285400003
EID of the result in the Scopus database
2-s2.0-85105763432